IDH1 and myeloproliferative neoplasm: The potential to achieve an even higher blast clearance rate in IDH-mutated patients with MPN-BP, using a triple combination of IDH inhibitor, Ven ± HMA has been suggested by recently published experience in the setting of IDH1-mutated myeloid malignancies (N = 31) with a composite complete remission rate of 83–90% [64]; IDH1 mutation clearance and MRD-negative status were documented in the majority of patients.